Life Molecular Imaging expands Neuraceq production in Southern California to meet growing Alzheimer’s diagnostic demand

Life Molecular Imaging, a subsidiary of Lantheus Holdings Inc. (NASDAQ: LNTH), has expanded the manufacturing and distribution network for its flagship diagnostic agent Neuraceq (florbetaben F-18 injection) in Southern California. The company announced that its first Los Angeles–based production run delivered doses on August 13, 2025, marking an important step in broadening access to Alzheimer’s diagnostic imaging across one of the most densely populated medical markets in the United States.

The move highlights a wider industry trend in which radiopharmaceutical developers are racing to expand geographical supply networks, as demand for amyloid PET scans grows in lockstep with the approval and adoption of anti-amyloid therapies for Alzheimer’s disease. For Life Molecular Imaging, the Southern California expansion not only addresses rising patient and physician demand but also strengthens its footprint in a region with some of the highest concentrations of neuroscience research institutions and memory care centers in the country.

Why is Neuraceq expansion in Los Angeles significant for Alzheimer’s patients?

Neuraceq is an FDA-approved radioactive diagnostic agent used to detect amyloid plaques in the brain of adults experiencing cognitive impairment. These plaques are a hallmark of Alzheimer’s disease and related neurodegenerative conditions, making amyloid PET imaging a crucial step in confirming diagnosis and evaluating treatment eligibility. The company noted that increasing local access to Neuraceq ensures that patients in San Diego, Los Angeles, and surrounding Southern California communities no longer need to rely exclusively on distant supply hubs for timely imaging availability.

Historically, PET radiopharmaceuticals like Neuraceq have faced logistical hurdles, primarily due to the short half-life of radioisotopes, which necessitates production near end-user facilities. By establishing Los Angeles as a production and distribution hub, Life Molecular Imaging reduces turnaround times, lowers the risk of delivery delays, and strengthens reliability for clinicians who must schedule imaging around narrow radiotracer viability windows.

The Southern California market also represents a dense cluster of Alzheimer’s clinical trial sites and neurology practices. With multiple new therapies recently approved by the U.S. Food and Drug Administration targeting amyloid reduction, demand for confirmatory PET scans has surged. Industry analysts suggest that imaging volumes could double over the next three years in markets where anti-amyloid drugs are widely adopted, positioning Life Molecular Imaging to benefit from both clinical routine use and research-driven demand.

How does Neuraceq fit into the broader Alzheimer’s diagnostic landscape?

The role of amyloid PET imaging has shifted dramatically over the past decade. When Neuraceq first received FDA approval in 2014, amyloid imaging was primarily used in research settings and for differential diagnosis in complex clinical cases. At that time, Alzheimer’s treatment options were limited to symptomatic therapies, and confirming amyloid burden offered little therapeutic utility beyond diagnostic clarity. However, the approval of disease-modifying therapies that specifically target amyloid has transformed amyloid imaging into a gateway test for treatment access.

Neuraceq competes in a market with other approved amyloid imaging agents, including Eli Lilly’s Amyvid (florbetapir F-18) and GE Healthcare’s Vizamyl (flutemetamol F-18). The competitive landscape has grown more intense as pharmaceutical companies pursue partnerships with diagnostic firms to secure imaging access for patients eligible for new Alzheimer’s drugs. Life Molecular Imaging’s strategy of geographic expansion addresses a critical bottleneck: ensuring consistent tracer availability in key metropolitan hubs.

Beyond Alzheimer’s disease, amyloid PET imaging is increasingly used in academic research, particularly in studies investigating the preclinical phases of dementia and related disorders. Southern California, with its ecosystem of leading medical schools, biotechnology startups, and federally funded Alzheimer’s research initiatives, represents fertile ground for increased utilization.

What does the expansion reveal about Lantheus Holdings’ growth strategy?

Lantheus Holdings, the parent company of Life Molecular Imaging, has been strategically diversifying its portfolio of diagnostic and therapeutic radiopharmaceuticals. While best known historically for its cardiac imaging products, the company has leaned into oncology and neurology as growth categories. Neuraceq represents one of its high-value neurological assets, directly tied to the rapidly expanding Alzheimer’s therapeutics market.

In financial terms, Lantheus reported 2024 revenue of $1.4 billion, with diagnostic radiopharmaceuticals accounting for a significant portion of growth. The company has consistently outperformed consensus expectations on earnings per share (EPS), driven by strong adoption of its prostate cancer imaging product, Pylarify, and increasing traction for Neuraceq. Analysts have suggested that Alzheimer’s imaging could emerge as the company’s next major revenue driver, potentially contributing several hundred million dollars annually by the end of the decade.

The Los Angeles production expansion also signals operational discipline. By reducing reliance on third-party suppliers and distant production centers, Lantheus improves supply chain resilience, which has become a central theme for pharmaceutical companies in the post-pandemic era. Institutional investors have generally rewarded companies that demonstrate proactive infrastructure investments, particularly in growth markets like neurodegeneration diagnostics.

How are investors and analysts reacting to Lantheus Holdings’ Alzheimer’s positioning?

Shares of Lantheus Holdings (NASDAQ: LNTH) have reflected cautious optimism in 2025 trading. While the broader biotech sector has seen volatility amid macroeconomic uncertainty and Federal Reserve interest rate signals, LNTH has remained relatively resilient. As of mid-August 2025, the stock was trading near $87, representing a modest gain year-to-date. Institutional flows suggest balanced positioning, with hedge funds modestly increasing exposure during Q2, while retail sentiment has leaned toward a “hold” outlook, reflecting caution about near-term reimbursement dynamics for Alzheimer’s drugs.

Analysts covering the company have emphasized the importance of Alzheimer’s imaging as a diversification lever. Several equity research notes in July pointed out that as anti-amyloid drugs gain Medicare reimbursement clarity, the volume of patients requiring amyloid PET confirmation could sharply rise. For investors, this translates into a potentially durable demand stream for Neuraceq, albeit one that may take multiple quarters to fully materialize as healthcare systems adapt to reimbursement structures.

From a trading perspective, LNTH has attracted steady institutional inflows but faces valuation constraints relative to peers. The company trades at a forward price-to-earnings ratio slightly above the diagnostic imaging sector average, indicating investor confidence but also underscoring expectations that Alzheimer’s imaging growth must translate into tangible revenue acceleration. Market sentiment currently favors a cautious “buy” rating, with analysts highlighting upside tied to execution in newly expanded geographies like Southern California.

What are the implications for patients and healthcare providers in California?

For patients in Southern California, the immediate implication is improved access to timely amyloid imaging, a critical step in determining eligibility for emerging Alzheimer’s treatments. Until recently, many patients faced logistical challenges, including long wait times and extended travel distances, to access diagnostic imaging doses produced in more distant hubs. The Los Angeles expansion reduces these barriers, enabling neurologists and memory clinics to integrate amyloid PET into standard diagnostic pathways more seamlessly.

Healthcare providers stand to benefit as well. By ensuring a reliable local supply of Neuraceq, imaging centers can increase scheduling efficiency and reduce the likelihood of canceled scans due to tracer delivery delays. This reliability could also strengthen provider confidence in offering amyloid PET as a routine service, further embedding the technology into standard Alzheimer’s care.

Could this expansion accelerate adoption of anti-amyloid therapies?

Analysts widely expect that improved access to diagnostic imaging will accelerate adoption of anti-amyloid therapies. These treatments, while groundbreaking, require definitive confirmation of amyloid pathology, making PET imaging indispensable. In markets where imaging access is limited, treatment uptake has been slower than anticipated. Conversely, in regions with robust imaging infrastructure, patient throughput has been more aligned with projections.

By targeting Southern California—a region with one of the largest aging populations in the U.S.—Life Molecular Imaging directly addresses one of the bottlenecks to treatment access. Industry observers suggest that such expansions will not only drive diagnostic volumes but could also positively influence prescribing patterns for neurologists, who may gain confidence in offering new therapies knowing that diagnostic confirmation is more readily accessible.

Life Molecular Imaging’s decision to anchor Neuraceq production in Los Angeles underscores the company’s role in bridging a critical gap in Alzheimer’s care: ensuring that diagnostic access keeps pace with therapeutic innovation. For Lantheus Holdings, the expansion strengthens its foothold in neurology, offering a pathway to diversify revenue and satisfy investor expectations in a sector defined by high growth potential but equally high execution risk. For patients and providers, it represents a tangible step toward more accessible, timely, and reliable Alzheimer’s diagnostics at a moment when demand is surging.